Disease-specific reference case extension: Management of overweight and obesity in adults Methods / process manual consultation NICE process and methods 3 December 2025 Ripretinib for treating ...

This guideline covers recognising, assessing and treating mental health problems in women who are planning to have a baby, are pregnant, or have had a baby or been pregnant in the past year. It covers ...

Critical assessment of evidence to help you make decisions. Advice, rather than formal NICE guidance.

Critical assessment of evidence to help you make decisions. Advice, rather than formal NICE guidance.

This guideline has been updated and replaced by NICE rapid guideline on managing COVID-19 (NG191) ...

Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy Technology appraisal ...

This guideline covers interventions in the acute stage of a stroke or transient ischaemic attack (TIA). It offers the best clinical advice on the diagnosis and acute management of stroke and TIA in ...

Suggested remit: To appraise the clinical and cost effectiveness of belantamab mafodotin within its marketing authorisation for treating relapsed or refractory multiple myeloma after 4 or more ...

May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. For people with COPD see our guideline on diagnosing ...

Suggested remit: To appraise the clinical and cost effectiveness of lecanemab within its marketing authorisation for treating mild cognitive impairment or mild dementia caused by Alzheimer’s disease.

This guideline has been updated and replaced by the NICE guideline on asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN) [NG245] ...

Suggested remit: To appraise the clinical and cost effectiveness of nusinersen and risdiplam within their marketing authorisations for treating spinal muscular atrophy.